PMID- 37773687
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 30
IP  - 1
DP  - 2024 Jan
TI  - Clinical Efficacy of Neoadjuvant Chemotherapy plus Modified Radical Mastectomy 
      for Stage II-III Breast Cancer Patients and Its Influence on Serum Tumor Markers.
PG  - 260-264
LID - AT8648 [pii]
AB  - OBJECTIVE: This research aims to assess the clinical efficacy of neoadjuvant 
      chemotherapy (NACT) in combination with modified radical mastectomy (MRM) for 
      stage II-III breast cancer (BC) patients and its impact on serum tumor markers 
      (STMs). METHODS: The study included 119 stage II-III BC patients treated between 
      June 2018 and June 2021. Among them, 55 cases underwent MRM (reference group), 
      while 64 cases received NACT followed by MRM (research group). We compared 
      intraoperative parameters (blood loss, operation time, hospital stay), clinical 
      outcomes, the incidence of postoperative adverse events (AEs), changes in STMs 
      (CA125, CA153, CEA), and one-year postoperative quality of life (QOL). RESULTS: 
      In comparison to the reference group, the research group exhibited significantly 
      lower intraoperative blood loss, shorter operation times, reduced hospital stays, 
      and higher rates of disease remission. Notably, the research group experienced a 
      lower overall incidence of AEs, including skin flap necrosis, subscalp effusion, 
      infection, and upper limb lymphedema. Postoperatively, all STMs in the research 
      group exhibited statistically significant reductions and were lower than those in 
      the reference group. Additionally, all QOL subscales demonstrated improvements 
      and higher scores in the research group. CONCLUSIONS: NACT followed by MRM 
      represents an effective approach for enhancing surgical outcomes and clinical 
      efficacy in stage II-III BC patients. This combination therapy also reduces the 
      risk of postoperative AEs and leads to favorable changes in STMs and 
      postoperative QOL levels.
FAU - Yan, Shuixin
AU  - Yan S
FAU - Li, Jiadi
AU  - Li J
FAU - Chen, Jiafeng
AU  - Chen J
FAU - Zhou, Yuxin
AU  - Zhou Y
FAU - Qiu, Yu
AU  - Qiu Y
FAU - Chen, Yan
AU  - Chen Y
FAU - Wu, Weizhu
AU  - Wu W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/drug therapy/surgery
MH  - Mastectomy, Modified Radical
MH  - Neoadjuvant Therapy
MH  - Quality of Life
MH  - Biomarkers, Tumor/therapeutic use
MH  - Mastectomy
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2023/09/29 18:42
MHDA- 2024/02/05 06:43
CRDT- 2023/09/29 15:40
PHST- 2024/02/05 06:43 [medline]
PHST- 2023/09/29 18:42 [pubmed]
PHST- 2023/09/29 15:40 [entrez]
AID - AT8648 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2024 Jan;30(1):260-264.